Atlantic Coastal Acquisition Corp II
ACAB

$10.95

0.45%

Market Cap: 89.4M

About: Atlantic Coastal Acquisition Corp II is a blank check company.

Employees: 4

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

17.99% less ownership

Funds ownership: 23.28% [Q4 2023] → 5.3% (-17.99%) [Q1 2024]

47% less funds holding

Funds holding: 15 [Q4 2023] → 8 (-7) [Q1 2024]

77% less capital invested

Capital invested by funds: $27M [Q4 2023] → $6.22M (-$20.8M) [Q1 2024]

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ACAB.

See Analyst Rankings

Financial journalist opinion

Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company's securities on Nasdaq.

Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

See News Rankings